PACIFIC-4
Short Title: PACIFIC-4
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with standard of care SBRT versus placebo with standard of care SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC. An additional cohort will assess Osimertinib following SBRT in patients with early stage unresected T1 to T3N0M0 NSCLC harbouring an EGFR mutation.
Study Number:
D9103C00001
Study Status:
Enrolling
Treatment Agent:
Durvalumab, Osimertinib (single-arm, open-label)
Resources and Links
National Clinical Trial Identified Number: NCT03833154
Disease:
- Non-Small Cell Lung Cancer
Study Phase:
III
ResearchCancer@CooperHealth.edu
Article Title
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer
Index Extra:
Lung, thoracic
Hide from Search:
Off
Physician Name:
Department: